Phase I Study of Safety and Immunogenicity of Ad4-HIV Vaccine Vectors in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2019
Price : $35 *
At a glance
- Drugs Ad4-EnvC150 (Primary) ; Ad4-EnvC150 (Primary) ; Ad4-mGag (Primary) ; Ad4-mGag (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 09 Apr 2019 Status changed from active, no longer recruiting to completed.
- 13 Feb 2019 Planned primary completion date changed from 31 Jan 2019 to 1 Jan 2020.
- 24 Apr 2018 Planned End Date changed from 1 Feb 2020 to 1 Jan 2020.